Pair Name	Morusin, MAPK pathway inhibitors
Partner Name	MAPK pathway inhibitors
Disease Info	[ICD-11: 2C30]	Melanoma		Investigative
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BIRC5	hsa332
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Expression	MYC	hsa4609
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	PCNA	hsa5111
	Down-regulation	Expression	SOX2	hsa6657
	Down-regulation	Phosphorylation	STAT3	hsa6774
In Vitro Model	A-375	Amelanotic melanoma	Homo sapiens (Human)	CVCL_0132
In Vivo Model	A375 and A375R cells (1×10⁵, in 100 μL of phosphate-buffered saline) were subcutaneously injected into the right hind legs of 4-week-old male BALB/c nude mice.
Result	Our results suggested that the combination of morusin and MAPK pathway inhibitors may be a more effective treatment strategy for BRAF-mutant melanoma than MAPK pathway inhibitors alone.

Pair Name	Morusin, TNF-related apoptosis inducing ligand
Partner Name	TNF-related apoptosis inducing ligand
Disease Info	[ICD-11: 2A00]	Glioblastoma multiforme		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BIRC5	hsa332
	Down-regulation	Expression	EGFR	hsa1956
	Down-regulation	Phosphorylation	STAT3	hsa6774
	Up-regulation	Expression	TNFRSF10B	hsa8795
	Down-regulation	Expression	XIAP	hsa331
In Vitro Model	U-251MG	Astrocytoma	Homo sapiens (Human)	CVCL_0021
	LN-18	Glioblastoma	Homo sapiens (Human)	CVCL_0392
Result	These results suggest that morusin enhances TRAIL sensitivity in human glioblastoma cells through regulating expression of DR5 and EGFR. Therefore, the combination treatment of TRAIL and morusin may be a new therapeutic strategy for malignant glioma patients.